Mandate

Vinge Advises Sunstone Capital on the Investment in CMC Contrast

February 27, 2008

Vinge advises Sunstone Capital on the investment in CMC Contrast. CMC Contrast develops the CMC 001 product. The product can be found on the market for international pharmaceuticals. The investment will contribute to further the development of the product and continued clinical studies.

Sunstone Capital is represented by partner Johan Winnerblad joined by associate Jonas Bergström.

Related

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026